MEDICAL PRODUCT ALERT

DRAP ALERT NO. Nº I/S/07-22-18

PRESENCE OF FALSIFIED GLUCANTIME (MEGLUMINE ANTIMONATE) IN QUETTA

(PURPORTED TO BE MANUFACTURED BY M/S. TILLOTTS PHARMA AG, SWITZERLAND)

Date: 05th August, 2022.

Target Audience:

- Physicians, Pharmacists, Nurses and General Public.

Alert Summary:

Analyst, Incidents and Substandard/Falsified Medical Products (ISF), Regulation and Safety Unit, World Health Organization has informed Drug Regulatory Authority of Pakistan that on 21 July 2022, suspected falsified GLUCANTIME (Meglumine Antimoniate) was identified in Quetta, Pakistan. The product was identified when a patient visited Sandeman Provincial Hospital, Quetta. It is suspected that the patient had purchased the falsified product from a nearby doctor in private practice.

The stated manufacturer listed on the falsified product is TILLOTTS PHARMA AG. Tillotts Pharma AG has confirmed to WHO that they do NOT manufacture, sub-contract the manufacture, nor distribute these products anywhere in the world.

Identification of the Falsified product:

The following discrepancies can be identified:

- The outer packaging has English and French labeling but contains visible spelling mistakes and questionable information
- Medicine - spelt "*medecine*"
- Use of a Gmail email address for manufacturers contact
- Statement that the product is an over the counter medicine

Pictures of Falsified product attached for reference.

DRAP, Islamabad
92 51 9107404
addl-dir.qa@dra.gov.pk

Pictures of Falsified product:

Action to be taken/ Advice for Healthcare Professionals and general public:

DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this subject mentioned falsified product.

If anyone is in possession of the above stated product batch, please do not use. If anyone has used subject mentioned product, or if anyone suffered an adverse reaction/event having used this product batch, it is advised to seek immediate medical advice from a qualified healthcare professional, and to report the incident to Drug Regulatory Authority of Pakistan/National Pharmacovigilance Centre.

DRAP, Islamabad
92 51 9107404
addl-dir.qa@dra.gov.pk